---
document_datetime: 2023-09-21 21:52:55
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/tezspire-epar-all-authorised-presentations_en.pdf
document_name: tezspire-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9231925
conversion_datetime: 2025-12-27 22:22:25.342515
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented ) name   | Strength   | Pharmaceuti cal Form   | Route of Administrati   | Immediate Packaging        | Content (concentration)   | Pack size                                |
|------------------|--------------------|------------|------------------------|-------------------------|----------------------------|---------------------------|------------------------------------------|
| EU/1/22/1677/001 | TEZSPIRE           | 210 mg     | Solution for injection | Subcutaneous use        | pre-filled syringe (glass) | 1.91 ml (110 mg/ml)       | 1 pre-filled syringe                     |
| EU/1/22/1677/002 | TEZSPIRE           | 210 mg     | Solution for injection | Subcutaneous use        | pre-filled syringe (glass) | 1.91 ml (110 mg/ml)       | 3 (3 x 1) prefilled syringes (multipack) |
| EU/1/22/1677/003 | TEZSPIRE           | 210 mg     | Solution for injection | Subcutaneous use        | pre-filled pen (glass)     | 1.91 ml (110 mg/ml)       | 1 pre-filled pen                         |
| EU/1/22/1677/004 | TEZSPIRE           | 210 mg     | Solution for injection | Subcutaneous use        | pre-filled pen (glass)     | 1.91 ml (110 mg/ml)       | 3 (3 x 1) prefilled pens (multipack)     |